Guidelines for hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society

Maturitas

Volumn 51, Issue 1, 2005, Pages 15-20

  Wright, Jean ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE;

BRAIN DISEASE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIET; FRAGILITY FRACTURE; HEART DISEASE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; PRACTICE GUIDELINE; QUALITY OF LIFE; STROKE; VENOUS THROMBOEMBOLISM;

AGED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EUROPE; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 18844398564     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.02.007     Document Type: Conference Paper

References (25)

1. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial J Am Med Assoc 288 2002 321 333
2. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
3. R.T. Chlebowski, S.L. Hendrix, and R.D. Langer Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial J Am Med Assoc 289 2003 3243 3253
4. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
5. D.W. Sturdee, and A. MacLennan HT or HRT, that is the question? Climacteric 6 2003 1
6. M. Gambacciani, and A.R. Genazzani The missing R Gynecol Endocrinol 17 2003 91 94
7. H. Kuhl Is the elevated breast cancer risk observed in the WHI study an artifact? Climacteric 7 2004 319 322
8. Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-12
9. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary disease in postmenopausal women J Am Med Assoc 280 1998 605 613
10. D.M. Herrington, D.R. Reboussin, and K.B. Brosnihan Effects of estrogen replacement on the progression of coronary artery atherosclerosis N Engl J Med 343 2000 522 529
11. J. Hays, J.K. Ockene, and R.L. Brunner Effects of estrogen plus progestin on health-related quality of life N Engl J Med 348 2003 1839 1854
12. F. Naftolin, H.S. Taylor, and R. Karas Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition Fertil Steril 81 2004 1498 1501
13. S. Shapiro Effects of HRT on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence. Climacteric Medicine - Where Do We Go? Schneider HPG F. Naftolin Proceedings of the 4th Workshop of the International Menopause Society 2004 Parthenon Publishing London, New York 166 174
14. R.A. Lobo Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from two large clinical trials Arch Intern Med 64 2004 482 484
15. M. Cushman, L.H. Kuller, and R. Prentice Estrogen plus progestin and risk of venous thrombosis J Am Med Assoc 292 2004 1573 1580
16. R.H. Karas, and T.B. Clarkson Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything Menopausal Med 10 2003 8 12
17. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941
18. F. Grodstein, M.J. Stampfer, and G.A. Colditz Postmenopausal hormone treatment and mortality N Engl J Med 336 1997 1769 1775
19. O. Joakimsen, K.H. Bønaa, E. Stensland-Bugge, and B.K. Jacobsen Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis J Clin Epidemiol 53 2000 525 530
20. F.B. Hu, M.J. Stampfer, and J.E. Manson Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women N Engl J Med 343 2000 530 537
21. W.J. Mack, A.B. Hameed, and M. Xiang Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial Atherosclerosis 168 2003 91 98
22. M.X. Tang, D. Jacobs, and Y. Stern Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease Lancet 348 1996 429 432
23. P.P. Zandi, M.C. Carlson, and B.L. Plassman Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study J Am Med Assoc 88 2002 2123 2129
24. M.R. Adams, J.R. Kaplan, and S.B. Manuck Inhibition of coronary atherosclerosis by 17β-estradiol in ovariectomized monkeys: lack of an effect of added progesterone Arteriosclerosis 10 1990 1051 1057
25. S.A. Shumakers, C. Legault, and L. Kuller Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study J Am Med Assoc 291 2004 2947 2958